Treatment Naïve Wet AMD

Sponsor: RegenexBio AAviate -Wet AMD

In this study, we are recruiting patients with wet AMD who are requiring repeated intravitreal anti-VEGF injections to maintain stability. This study utilizes a novel genetic therapy which codes for the “blueprint instructions” to teach the retinal cells to produce their own anti-VEGF molecule. This allows the eye to be its own factory of medication thus reducing the need for repeated injections. The genetic therapy is injected just under the surface of the eye during a one-time office procedure. Initial studies have shown both a favorable efficacy and safety profile.

For more information visit www.REGENXBIO.com